SYS-6020

N/A

Report date: 2024/10/28 17:17:13

Base Information

Drug NameSYS-6020
Drug Alias NameSYS6020SYS-6020
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsT lymphocyte replacements
TargetsB-cell maturation protein
Therapy Area/IndicationsLupus Erythematosus, SystemicMyasthenia GravisMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdWuhan Union HospitalCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicMyasthenia GravisMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A